Junxian Geng

The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel et al. · Cancer Discovery · 2023 · 83 citations · Full text

Probabilistic Community Detection With Unknown Number of Communities

Junxian Geng, Anirban Bhattacharya, Debdeep Pati · Journal of the American Statistical Association · 2018 · 80 citations

Cluster Computing, Engineering, Community Mining +17

Bayesian Spatial Homogeneity Pursuit of Functional Data: An Application to the U.S. Income Distribution

Guanyu Hu, Junxian Geng, Yishu Xue et al. · Bayesian Analysis · 2022 · 21 citations · Full text

Markov Random Field, Lorenz Curve, Data Science +19

Bayesian nonparametric nonhomogeneous Poisson process with applications to USGS earthquake data

Junxian Geng, Wei Shi, Guanyu Hu · Spatial Statistics · 2021 · 17 citations

Engineering, Seismology, Usgs Earthquake Data +8

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS).

Mrinal M. Gounder, Noboru Yamamoto, Manish R. Patel et al. · Journal of Clinical Oncology · 2022 · 11 citations

Mdm2-amplified Disease, Advanced/metastatic Liposarcoma, Bi 907828 +15